ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Inc (ACAD)

15.88
0.58
(3.79%)
At close: June 24 4:00PM
15.8008
-0.0792
( -0.50% )
After Hours: 7:05PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
15.8008
Bid
15.88
Ask
16.00
Volume
1,846,700
15.38 Day's Range 16.30
14.55 52 Week Range 33.99
Market Cap
Previous Close
15.30
Open
15.38
Last Trade Time
19:05:42
Financial Volume
$ 29,371,112
VWAP
15.9046
Average Volume (3m)
1,640,399
Shares Outstanding
165,220,884
Dividend Yield
-
PE Ratio
-42.79
Earnings Per Share (EPS)
-0.37
Revenue
726.44M
Net Profit
-61.29M

About Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks t... Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Acadia Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ACAD. The last closing price for Acadia Pharmaceuticals was $15.30. Over the last year, Acadia Pharmaceuticals shares have traded in a share price range of $ 14.55 to $ 33.99.

Acadia Pharmaceuticals currently has 165,220,884 shares outstanding. The market capitalization of Acadia Pharmaceuticals is $2.62 billion. Acadia Pharmaceuticals has a price to earnings ratio (PE ratio) of -42.79.

ACAD Latest News

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.03086.9790115098214.7716.314.61209829715.01011379CS
40.54083.5439056356515.2616.314.55150356615.07610517CS
12-2.7892-15.003765465318.5918.6314.55164039916.04586758CS
26-15.9492-50.233700787431.7531.9314.55173901220.72135744CS
52-8.6492-35.375051124724.4533.9914.55176291123.38645472CS
156-8.7492-35.638289205724.5533.9912.24167688820.76818548CS
260-10.2092-39.251057285726.0158.7212.24163547527.58903419CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GLYCGlycoMimetics Inc
$ 0.4396
(64.89%)
25.86M
SNTISenti Biosciences Inc
$ 0.3803
(50.91%)
9.77M
LGHLWLion Group Holding Ltd
$ 0.0094
(38.24%)
100
VLCNVolcon Inc
$ 5.20
(34.02%)
140.57k
ODPODP Corporation
$ 47.52
(21.85%)
8.19k
MLGOMicroAlgo Inc
$ 10.25
(-31.67%)
5.17M
XAIRBeyond Air Inc
$ 0.99
(-26.12%)
525.65k
FFIEFaraday Future Intelligent Electric Inc
$ 0.2449
(-24.88%)
11.6M
HGASGlobal Gas Corporation
$ 0.7416
(-24.33%)
68.1k
LIPOLipella Pharmaceuticals Inc
$ 0.53
(-16.14%)
313.68k
GLYCGlycoMimetics Inc
$ 0.4396
(64.89%)
25.86M
NVDANVIDIA Corporation
$ 116.949
(-0.98%)
17.02M
FFIEFaraday Future Intelligent Electric Inc
$ 0.2449
(-24.88%)
11.6M
SNTISenti Biosciences Inc
$ 0.3803
(50.91%)
9.77M
CRKNCrown Electrokinetics Corporation
$ 0.0364
(-4.96%)
9.17M

ACAD Discussion

View Posts
harry crumb harry crumb 4 weeks ago
Time to buy more
👍️0
harry crumb harry crumb 1 month ago
Been in
👍️0
girlfriend girlfriend 2 months ago
Good time to add or get in today!
👍️0
harry crumb harry crumb 4 months ago
Good time to add to the stash $$$$
👍️0
LasNubes LasNubes 5 months ago
Been in here a long time.

Off and on since the $1 range

Let’s go
👍️0
harry crumb harry crumb 6 months ago
You will soon enough
👍️0
harry crumb harry crumb 6 months ago
Boom
👍️0
IanFromSI IanFromSI 6 months ago

Acadia Pharmaceuticals surges 32% after win in patent suit over Nuplazid

Dec 13, 2023 10:15 AM ET | ACADIA Pharmaceuticals Inc. (ACAD) | Joshua Fineman, SA News Editor

Acadia Pharmaceuticals (NASDAQ:ACAD) jumped 32% after winning summary judgement in a patent suit regarding its drug Nuplazid, which is used to treat Parkinson's disease. Acadia won the judgement against generic maker MSN Laboratories.
"For the foregoing reasons, the Court grants summary judgement to Acadia," U.S. Disctrict Court Judge Gregory B. Williams wrote in a court opinion on Wednesday.
Acadia (ACAD) filed separate lawsuits last October alleging that copies of Nuplazid infringed a patent, including a lawsuit against MSN Laboratories
👍️0
IanFromSI IanFromSI 9 months ago
I should live so long
👍️0
harry crumb harry crumb 9 months ago
Oh it’l happen, enough said
👍️0
IanFromSI IanFromSI 9 months ago
Harry, I haven’t seen any buyout rumours for Acadia since March 2015. What are you talking about or hoping for?

Please provide a link.
👍️0
harry crumb harry crumb 9 months ago
27k shares waiting on the buyout news! Happy early retirement all over again
$$$$$$
👍️0
harry crumb harry crumb 9 months ago
Boom
👍️0
harry crumb harry crumb 11 months ago
Keeps going up here
👍️0
Monksdream Monksdream 11 months ago
ACAD new 52 week high
👍️0
harry crumb harry crumb 11 months ago
Boom
👍️0
IanFromSI IanFromSI 11 months ago
Shares of Acadia climbed 17% in after-hours trading Thursday.

Price: 30.25, Change: +4.45, Percent Change: +17.25



ACADIA Pharmaceuticals Acquires Ex-North America Rights to Trofinetide, Global Rights to NNZ-2591; Shares Rise After Hours
2023-07-13 05:26:11 PM ET (MT Newswires)


05:26 PM EDT, 07/13/2023 (MT Newswires) -- ACADIA Pharmaceuticals (ACAD) said Thursday it expanded its current licensing agreement for trofinetide, a treatment for Rett syndrome, with Neuren Pharmaceuticals to acquire ex-North American rights to the drug.

The agreement also gives Acadia global rights to Neuren's NNZ-2591 in Rett syndrome and Fragile X syndrome.

Under the agreement, Neuren will receive an upfront payment of $100 million and may receive potential downstream milestone and royalty payments earned separately for trofinetide and NNZ-2591.

Outside of North America, Neuren may receive additional payments for trofinetide upon the achievement of certain revenue milestones and it will also get tiered royalties from the mid-teens to low-twenties percent of trofinetide sales.

Potential future payments to Neuren related to NNZ-2591 in Rett syndrome and Fragile X syndrome are equal to the payments for trofinetide in each of North America and outside North America, Acadia said.

Acadia said it plans to submit a new drug submission for trofinetide in Canada in the next 18 months. It will announce plans for Europe, Asia and other regions at a later date.

Shares of Acadia climbed 17% in after-hours trading Thursday.

Price: 30.25, Change: +4.45, Percent Change: +17.25

👍️0
harry crumb harry crumb 1 year ago
Beautiful day $$$$
👍️0
Doktornolittle Doktornolittle 1 year ago
Is Martin Shkreli in charge of Acadia, or some other cold psycho-bstrd? Shkreli was released to a half way house in May of last year.

https://www.cnbc.com/2022/05/18/martin-shkreli-released-from-federal-prison-into-halfway-house-.html#:~:text=Shkreli%20was%20arrested%20in%20late,that%20he%20had%20covered%20up.

https://www.marketwatch.com/story/acadias-rare-disease-drug-to-cost-575-000-to-595-000-5e883843

https://news.sky.com/story/martin-shkreli-man-who-made-huge-profits-by-inflating-price-of-life-saving-drug-ordered-to-return-47m-12516161#:~:text=Data%20%26%20Forensics-,Martin%20Shkreli%3A%20Man%20who%20made%20huge%20profits%20by%20inflating%20price,rights%20to%20it%20in%202015.
👍️0
harry crumb harry crumb 1 year ago
30’s coming folks, patience
👍️0
MiamiGent MiamiGent 1 year ago
ACAD hopefully Opening will give a boost but I just got out with a meager profit, not appreciating P-M action. I'm playing for a batting average this year and keep my distance from red. GL!
👍️0
harry crumb harry crumb 1 year ago
If the price is right, yes
👍️0
my74nova my74nova 1 year ago
Or dumb for not selling when it was in the upper $50's years ago. ;)
👍️0
MiamiGent MiamiGent 1 year ago
Phew, $2.1>. Nice!
You are patient..
👍️0
my74nova my74nova 1 year ago
Mine are at $2.18.....been holding for a looong time. Hope we can get back into the upper $50's and maybe beyond.

Do you think anyone would want to do a buyout?
👍️0
MiamiGent MiamiGent 1 year ago
ACAD...... APPROVED!
👍️0
harry crumb harry crumb 1 year ago
Strong ticker
👍️0
harry crumb harry crumb 1 year ago
Still hold shares at 5.00 here
👍️0
harry crumb harry crumb 1 year ago
Nice day for acad holders??
👍️0
IanFromSI IanFromSI 1 year ago
$ACAD is covered by 10 analysts:

Sell zero
Neutral seven
Buy three

RBC Boosts Price Target on ACADIA Pharmaceuticals to $27 From $19, Maintains Outperform Rating
2023-02-28 08:14:38 AM ET (MT Newswires)


08:14 AM EST, 02/28/2023 (MT Newswires) -- ACADIA Pharmaceuticals (ACAD) has an average investment rating of hold among analysts polled by Capital IQ, with price targets ranging from $10 to $28.

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
👍️0
harry crumb harry crumb 1 year ago
Throughout market turmoil thanks to biden an his brainless entourage acad holding up well in portfolio’s $$$$
👍️0
harry crumb harry crumb 1 year ago
1 an 3 month chart are winners for those who added! $$$$
👍️0
harry crumb harry crumb 1 year ago
Lmao shorty, the BB’s are far more advanced than you, i kno them well, GL an in the trading world there is a word spelled c o v e r, If i were you i would look up what it means. Enough said, happy trading folks, patience…. $$$$
👍️0
gi197845 gi197845 2 years ago
An ironic twist of fate.
The law of unintended consequences.
Most of you are overly invested in Acadia pharma.
Most of you are deep underwater with your investment.
Most of you have averaged down and even taken out a 2nd mortgage to do so.
Most of you are hoping that Trofinetide will be FDA approved for RETT syndrome on March 12th, 2023.
Most of you think Acadia's share price will rise upon FDA approval.
Most of you are just hoping to break even to bail out of this Titanic boat anchor.
Most of you don't realize that the stock price will dive upon Trofinetide approval.
It costs more to manufacture and sell Trofinetide, than full sales could ever pay for let alone make a profit.
The same is true of Nuplazid, it costs more to manufacture and sell, than any meager "profits" can bring in.
The Baker Brothers only own Acadia pharma stock, as a tax write-off...
Every hedge fund, needs one bad apple in the bunch, just to offset taxes on the other, profitable holdings.
Criss-Cross, you bet the wrong dog!
👍️0
gi197845 gi197845 2 years ago
The volume today has been only the selling of shares, back into the public float/pool, no one is buying shares, hence the downward pressure on the stock price. It's simply not true that for every seller, there is a buyer, there are many shares still in the public float that Acadia owns, to sell into the market, for their own financial gain, when and if those shares are purchased. When a person buys a stock out of the public float pool, that money goes directly into Acadia's pockets...
👍️0
LasNubes LasNubes 2 years ago
Pretty standard stuff.
Most Pharma companies have legal issues like this.

None of this will move the needle in either direction IMHO
👍️0
gi197845 gi197845 2 years ago
OK, that's good but what about this?
https://www.lawow.org/karp-vs-acadia-pharmaceuticals-inc-2021-11-22/
2 people died because Acadia illegally hired a convicted felon as a pharma sales, rep that sold them fentanyl. Unlimited damages and liabilities. Why would Acadia hire a felon? Why does Stephen Davis have his shirt unbuttoned down so far during conference calls?

Uh Oh! what about this lawsuit??? Hmmm...????

NEW ORLEANS, Nov. 11, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD).

On July 20, 2020, the Company announced that the FDA had accepted for filing its supplemental new drug application ("sNDA") for its drug candidate, pimavanserin, for the treatment of dementia-related psychosis ("DRP"). Thereafter, the company repeatedly stated the FDA had not identified any potential review issues and reiterated the drug's efficacy. Then, on April 5, 2021, the Company disclosed that the FDA had rejected the sNDA, citing a lack of statistical significance regarding some of the subgroups of dementia and inadequate numbers of patients with some less common dementia subtypes.
👍️0
LasNubes LasNubes 2 years ago
ACAD is the plaintiff and filed suit due to patent infringement claims.

This is pretty standard stuff and actually good for ACAD that their patent attorneys are going after folks trying to jump their patents.
👍️0
gi197845 gi197845 2 years ago
Wow, yet another lawsuit!

https://casetext.com/case/acadia-pharm-v-aurobindo-pharma
👍️0
gi197845 gi197845 2 years ago
Uh oh, Acadia going out of business due to 2 wrongful death lawsuits, with unlimited damages.

https://www.lawow.org/karp-vs-acadia-pharmaceuticals-inc-2021-11-22/
👍️0
harry crumb harry crumb 2 years ago
Good pop today
👍️0
harry crumb harry crumb 2 years ago
Things like that happen with bio’s, it’’s still a promising company to invest in, theres other drug science capable of moving forward just like any other. those who followed us from the beginning of acad, at 2-5$ a share made a ton of wealth over the years whether they flipped in or out at variable times was their choice, its called trading, making wealth. To invest 25k at 3$ pps and to sell at 50 pps is a very large gain of wealth my friend. Those who didn’t sell well don’t blame acad for that. You think the BB’s invested not to sell? Ah, no they sure didn’t. We hold a chunk of acad yet but that is all free shares, no matter what price it goes to. As for other stocks you mentioned, it’s the same, wealth made an just sitting on free shares, who really cares what happens once your initial investment is paid for in gains. GL to you an never be greedy, take profits as u wish
👍️0
gi197845 gi197845 2 years ago
What about the latest shelf offering and the lowered guidance? Do you enjoy it?
👍️0
harry crumb harry crumb 2 years ago
Ah listen pal, before u make a comment you should know what exactly your commenting on! Acad has made investors millions of dollars since the beginning stages of its first trial an first nda! I guess you do not know this, over the years investing in this company has been nothing but positive an for someone like you to comment on an issue you have no clue about is absurd! Get lost an go crawl under a rock
👍️0
gi197845 gi197845 2 years ago
Big mistake listening to Harry Crumb! Keep in mind that he invested in a used car salesman owned scam with with water less tooth brushes and paper less toilet paper.
👍️0
gi197845 gi197845 2 years ago
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID(R) (pimavanserin) for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP).

The CRL indicated that the FDA has completed review of the application, determining that it could not approve the sNDA in its present form, and recommended that Acadia conduct an additional trial in ADP. While the FDA stated that Study 019 demonstrated a statistically significant treatment effect on its primary endpoint, they concluded that there are limitations in the interpretability of the 019 results. The FDA also stated that the positive treatment effect of pimavanserin on dementia-related psychosis in Study 045 (HARMONY) appeared to be driven by the robustly positive results in the Parkinson's disease dementia subgroup, a condition they stated is subsumed within the currently approved NUPLAZID Parkinson's disease psychosis (PDP) indication. Up to 50 percent of PDP patients have dementia.(1)

"We are disappointed with this outcome. The treatment of Alzheimer's disease psychosis continues to be an area of high unmet need, for which there is no approved therapy," said Steve Davis, Chief Executive Officer. "We want to express our gratitude to all of the patients, their families and investigators who have participated in our clinical trials."

NUPLAZID was approved in the U.S. in 2016 and is the first and only treatment for hallucinations and delusions associated with PDP.
👍️0
gi197845 gi197845 2 years ago
Smell my shorts, shortie! In your face!
👍️0
gi197845 gi197845 2 years ago
State of New Jersey Common Pension Fund D trimmed its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) by 34.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 96,642 shares of the biopharmaceutical company’s stock after selling 50,023 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in ACADIA Pharmaceuticals were worth $2,341,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the stock. Lazard Asset Management LLC grew its position in shares of ACADIA Pharmaceuticals by 19.4% in the 4th quarter. Lazard Asset Management LLC now owns 3,115 shares of the biopharmaceutical company’s stock valued at $72,000 after buying an additional 506 shares during the last quarter. Personal CFO Solutions LLC grew its position in shares of ACADIA Pharmaceuticals by 6.7% in the 1st quarter. Personal CFO Solutions LLC now owns 15,846 shares of the biopharmaceutical company’s stock valued at $384,000 after buying an additional 1,000 shares during the last quarter. Kalos Management Inc. grew its position in shares of ACADIA Pharmaceuticals by 6.0% in the 4th quarter. Kalos Management Inc. now owns 19,689 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 1,114 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of ACADIA Pharmaceuticals by 8.0% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,927 shares of the biopharmaceutical company’s stock valued at $434,000 after buying an additional 1,334 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale grew its position in shares of ACADIA Pharmaceuticals by 2.7% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 68,700 shares of the biopharmaceutical company’s stock valued at $1,637,000 after buying an additional 1,800 shares during the last quarter. 91.74% of the stock is owned by hedge funds and other institutional investors.
👍️0
gi197845 gi197845 2 years ago
I figured it out. The only reason why the successful baker brothers have shares of Acadia is for tax right off purposes, to offset the huge profits from their other well managed pharmas.
👍️0
gi197845 gi197845 2 years ago
Hey foo, I hope your shorting this!
👍️0

Your Recent History

Delayed Upgrade Clock